Search

Coloplast A-S (Class B)

Ouvert

549.4

Résumé

Variation du prix de l'action

24h

Actuel

Min

541.2

Max

553.8

Chiffres clés

By Trading Economics

Revenu

70M

875M

Ventes

2M

7B

P/E

Moyenne du Secteur

33.486

89.037

BPA

3.88

Rendement du dividende

4.24

Marge bénéficiaire

12.572

Employés

16,744

EBITDA

2B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+11.86% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

4.24%

2.18%

Prochains Résultats

6 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-947M

122B

Ouverture précédente

549.4

Clôture précédente

549.4

Coloplast A-S (Class B) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 janv. 2026, 21:55 UTC

Résultats

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22 janv. 2026, 23:52 UTC

Résultats

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22 janv. 2026, 23:48 UTC

Market Talk

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22 janv. 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22 janv. 2026, 23:40 UTC

Market Talk

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22 janv. 2026, 23:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 janv. 2026, 23:30 UTC

Market Talk

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22 janv. 2026, 22:37 UTC

Market Talk
Acquisitions, Fusions, Rachats

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22 janv. 2026, 21:59 UTC

Acquisitions, Fusions, Rachats

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22 janv. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

22 janv. 2026, 21:44 UTC

Résultats

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22 janv. 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22 janv. 2026, 21:31 UTC

Acquisitions, Fusions, Rachats

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22 janv. 2026, 21:31 UTC

Acquisitions, Fusions, Rachats

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22 janv. 2026, 21:30 UTC

Résultats

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22 janv. 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

Capital One To Acquire Brex >COF

22 janv. 2026, 21:13 UTC

Résultats

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22 janv. 2026, 21:11 UTC

Résultats

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22 janv. 2026, 21:11 UTC

Résultats

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22 janv. 2026, 21:10 UTC

Résultats

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22 janv. 2026, 21:06 UTC

Résultats

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q Rev $15.58B >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q EPS $3.26 >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q Net Interest Margin 8.26% >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q Net $2.13B >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q Adj EPS $3.86 >COF

22 janv. 2026, 21:05 UTC

Résultats

Capital One 4Q Net Charge-Offs $3.8B >COF

22 janv. 2026, 21:05 UTC

Résultats

Intuitive Surgical 4Q EPS $2.21 >ISRG

Coloplast A-S (Class B) prévision

Objectif de Prix

By TipRanks

11.86% hausse

Prévisions sur 12 Mois

Moyen 901.38 DKK  11.86%

Haut 1,056 DKK

Bas 720 DKK

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

8 ratings

2

Achat

4

Maintien

2

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat